Novartis remibrutinib trial data in Phase III RMS
TradingView reports Phase III RMS results for Novartis remibrutinib, an oral BTK inhibitor, citing reduced relapse rates and a favorable safety profile.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.